Author: Ntokozo Msiza

19 November 2020 The Backlog Clearance Team has been made aware of a miscommunication in our Newsletter dated August 2020 and we would like to clarify the matter. It relates to the submission of Type I & II variation applications and states that Type I variations...

12 November 2020 SAHPRA wishes to correct the inaccuracies in the Medical Brief article titled “High Court rules that SAHPRA not to regulate alternative medicines” published on 4 November 2020. On 01 October 2020, the Pretoria High Court delivered its judgment in the matter between the...

The South African Health Products Regulatory Authority (SAHPRA), in collaboration with other regulatory agencies, are reviewing all ranitidine-containing medicines with the following Active Pharmaceutical Ingredient; ranitidine. SAHPRA previously issued a media release regarding the recall and quarantine of ranitidine containing medicines (29 October 2019 and...